UNITED STATES
                        SECURITIES AND EXCHANGE COMMISSION

                             Washington, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT
                       Pursuant to Section 13 or 15(d) of
                       the Securities Exchange Act of 1934

      Date of Report (Date of earliest event reported): December 9, 2005

                     INTEGRA LIFESCIENCES HOLDINGS CORPORATION
               (Exact name of Registrant as specified in its charter)



   Delaware                            0-26224                   51-0317849
(State or other jurisdiction of (Commission File Number)      (I.R.S. Employer
 incorporation or organization)                              Identification No.)
 

                              311 Enterprise Drive
                              Plainsboro, NJ 08536
               (Address of principal executive offices) (Zip Code)

       Registrant's telephone number, including area code: (609) 275-0500

                                 Not Applicable
          (Former name or former address, if changed since last report)


Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:

[ ] Written communications pursuant to Rule 425 under the Securities Act 
    (17 CFR 230.425)

[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act 
    (17 CFR 240.14a-12)

[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
    Act (17 CFR 240.14d-2(b))

[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange
    Act (17 CFR 240.13e-4(c))







ITEM 8.01.  OTHER EVENTS.

On December 9, 2005, the waiting period under the Hart-Scott-Rodino Antitrust
Improvements Act of 1976, as amended, relating to the pending acquisition of the
assets of the Radionics Division of Tyco Healthcare Group LP from Tyco
Healthcare Group LP and Sherwood Services, AG by Integra LifeSciences
Corporation and Integra LifeSciences (Ireland) Limited, wholly owned
subsidiaries of Integra LifeSciences Holdings Corporation ("Integra"), expired.

Completion of the acquisition remains subject to customary closing conditions,
including a fiscal year-end financial audit. Integra currently contemplates that
the closing will occur during the first quarter of 2006.

A copy of the press release issued by the Company is attached as Exhibit 99.1 to
this Current Report on Form 8-K and is incorporated by reference into this Item.


ITEM 9.01.  FINANCIAL STATEMENTS AND EXHIBITS.

(c) Exhibits.

Exhibit Number   Description of Exhibit
--------------   ---------------------------

99.1             Press release issued December 12, 2005






                                   SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned, hereunto duly authorized.

                    INTEGRA LIFESCIENCES HOLDINGS CORPORATION

       Date: December 15, 2005         By: /s/ Stuart M. Essig
                                           -----------------------------
                                           Stuart M. Essig
                                           President and Chief Executive Officer





                                  Exhibit Index


Exhibit Number   Description of Exhibit
--------------   ---------------------------

99.1             Press release issued December 12, 2005